Sentinel node in breast cancer as an indicator of quality in medical care: Evaluation of statistics in Colombia.

Breast disease Pub Date : 2024-04-08 DOI:10.3233/bd-230059

Mario Arturo González Mariño

{"title":"Sentinel node in breast cancer as an indicator of quality in medical care: Evaluation of statistics in Colombia.","authors":"Mario Arturo González Mariño","doi":"10.3233/bd-230059","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nSentinel lymph node biopsy in breast cancer is considered the standard of staging in cases of clinically negative lymph nodes. Its omission in favor of axillary dissection generates significant morbidity.\n\n\nOBJECTIVE\nTo determine the total number of sentinel node biopsy procedures in breast cancer in Colombia from 2017 through 2020, model and analyze them as if they were performed only in stage I breast cancer patients, and integrate their results into the concepts of quality of medical care.\n\n\nMETHODS\nSearch in a database of the Ministry of Health and Social Protection of Colombia with sentinel lymph node biopsy codes, and filters of breast cancer and year. Their results are contrasted with the number of cases in stage I of breast cancer.\n\n\nRESULTS\nBreast cancer TNM staging was reported in 22154 cases, 3648 stage I. In the same time frame, the number of sentinel lymph node biopsies for breast cancer in Colombia was 1045, 28.64% of the total cases reported in stage I.\n\n\nCONCLUSIONS\nColombia is far from complying with the standard indicator of sentinel lymph node biopsy. It is recommended to concentrate breast cancer cases in hospitals that provide the conditions for its performance.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"217 1","pages":"65-69"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/bd-230059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND Sentinel lymph node biopsy in breast cancer is considered the standard of staging in cases of clinically negative lymph nodes. Its omission in favor of axillary dissection generates significant morbidity. OBJECTIVE To determine the total number of sentinel node biopsy procedures in breast cancer in Colombia from 2017 through 2020, model and analyze them as if they were performed only in stage I breast cancer patients, and integrate their results into the concepts of quality of medical care. METHODS Search in a database of the Ministry of Health and Social Protection of Colombia with sentinel lymph node biopsy codes, and filters of breast cancer and year. Their results are contrasted with the number of cases in stage I of breast cancer. RESULTS Breast cancer TNM staging was reported in 22154 cases, 3648 stage I. In the same time frame, the number of sentinel lymph node biopsies for breast cancer in Colombia was 1045, 28.64% of the total cases reported in stage I. CONCLUSIONS Colombia is far from complying with the standard indicator of sentinel lymph node biopsy. It is recommended to concentrate breast cancer cases in hospitals that provide the conditions for its performance.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

作为医疗质量指标的乳腺癌前哨结节：评估哥伦比亚的统计数据。

背景乳腺癌前哨淋巴结活检被认为是临床淋巴结阴性病例的分期标准。目的确定 2017 年至 2020 年哥伦比亚乳腺癌前哨淋巴结活检的总数量，建立模型并进行分析，将其视为仅在 I 期乳腺癌患者中进行，并将其结果纳入医疗质量的概念中。方法在哥伦比亚卫生和社会保障部的数据库中搜索前哨淋巴结活检代码、乳腺癌过滤器和年份。结果哥伦比亚报告的乳腺癌 TNM 分期病例为 22154 例，I 期病例为 3648 例。同一时期，哥伦比亚乳腺癌前哨淋巴结活检病例为 1045 例，占 I 期病例总数的 28.64%。建议将乳腺癌病例集中到有条件进行前哨淋巴结活检的医院。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.